To CRISPR or not to CRISPR? Group 2 Ethics of technology and science: Seminar II.

Slides:

Advertisements

Similar presentations

PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.

Advertisements

Merck and River Blindness

Stem Cells & Cloning 3/23/05 Bio Ethics Timeline and Controversies.

Implications Of Selective Breeding, Cloning & Genetic Engineering D. Crowley, 2007.

Should the government prohibit research in the field of human genetic engineering? by Maggie Fleming.

Finding Funding in Medical Research Professor Peter Ratcliffe Nuffield Department of Medicine.

Human Genetics Overview.

Chapter 17.5 Gene expression and Mutations

Meet the Gene Machine Basic Genetics & Background on Genetic Testing.

Genetic Engineering: Some Basic Concepts. DNA: The Information Carrier.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Genetic Testing and Gene Therapy  Catalyst (on a sheet of loose leaf) 1. Does the pedigree to the right show a disorder that is dominant or recessive?

Medical Achievements Cancer, AIDS, Stem Cell. Cancer Achievements O Newer drugs seem to be making a bigger difference for small, specific groups of patients,

GRESHAM LECTURE I Reproductive Technologies and the birth of Regulation.

S4 Revision Medical Ethics. SQA National Grade Boundaries BandGrademark 1.A upper A lower B upper B lower C upper

Biotechnology with a Conscience - Bioethics

Transgenic and Evolution By Emily Norovsambuu. What is transgenic? If a gene or genes that have been transferred from a different species to unlike species.

Legal Policy and Chronic Disease Control: Avoiding Unintended Consequences Edward P. Richards Director, Program in Law, Science, and Public Health Harvey.

Gene Therapy is the Path to a Cure Keith R. Jerome, MD, PhD Fred Hutchinson Cancer Research Center Seattle, Washington USA.

Seong-Eui Hong. Background

Privacy Debate: Urgent Issue or Industry Hype? Getting Better all the time Can’t get no worse Bridging the Alan Chapell.

By: Ashley Payne and Katelyn Cassady. Gene Therapy is a fast growing field of medicine where genes are inserted into the body to treat diseases. Genes.

The New Science of Food: Facing Up to Our Biotechnology Choices Prepared by Mark Edelman, Iowa State University David Patton, Ohio State University A Farm.

ELSI: Ethical, Legal and Social Issues surrounding availability of genomic information DOD and NIH devoted ~3-5% of annual HGP budgets to ELSI research.

Genomics, Gene Therapy and

An ethical problem in science Hwei-yen Andres Lucie Murielle Jakub Valerie Eryn.

1 Clinical trials with stem cells Bernard Lo, M.D. February 12, 2009.

What is gene therapy? Do now: In your own words,

Playing God? The double-edged sword of DNA Daniel Coral 004C MEI.

Massachusetts General Hospital/ Harvard Medical School

What is... Gene Therapy?. Genes Specific sequence of bases that encode instructions on how to make genes. Genes are passed on from parent to child. When.

Meet the Gene Machine Basic Genetics & Background on Genetic Testing.

Genome Editing Katie Plummer.

Seminar 2 Ethics of Technology and Science February 11, 2016 Group 2 Martin Andersson Shaohui Chen Jessica Garcia Yuanyuan Han Sofia Kontos.

Ethics in technology and science Seminar II Kristina Johansson Viktor Renman Burak Aktekin Dan Wu Junxin Wang Group IV.

Seminar II Group 6 Per Fors Luimar Correa Filho Zhen Qiu Fengzhen Sun.

WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.

Designer Babies Adam Ibrahim Anjellica Williams Brooke Formby, Krystel Seguismundo Nicole Bravo, Valeria Simonetti.

STEM CELL RESEARCH. Overview In this activity, you will learn how cell specialization takes place in vertebrate embryos. –Explore a gallery of different.

Genetic Testing and Gene Therapy  Catalyst:  Why do you think this frog has six legs?

What do we need to know to become stem cell literate?

Ethics course seminar 1 Group 5

My life as a researcher. Fact or Fiction. How did I get here?

Ethics of Technology and Science

EpEditors David Hanly 29/09/16

What is ... Gene Therapy?.

CRISPR-Cas9 in development and genetic disease

Biotechnology Ms. Hughes Biology.

Basic Genetics & Background on Genetic Testing

Ethics in Biotechnology

Mutations & Genetic Engineering

Manipulating an organism’s genome using biotechnology

Ethics and impacts of biotechnology

KEY CONCEPT Genetics provides a basis for new medical treatments.

Basic Genetics & Background on Genetic Testing

KEY CONCEPT Genetics provides a basis for new medical treatments.

Alexandra M. Dainis, and Euan A. Ashley BTS 2018;3:

CRISPR CRISPRs (clustered regularly interspaced short palindromic repeats) are repetitive nucleotide sequences followed by a short spacer DNA segments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9

Gene therapy Gene therapy aims to treat a disease by supplying a functional allele One possible procedure Clone the functional allele and insert it in.

Second International Summit on Human Genome Editing

CRISPR: What is it? Biotech Ethics, Fall ‘18.

Advances in Genetics.

KEY CONCEPT Genetics provides a basis for new medical treatments.

KEY CONCEPT Genetics provides a basis for new medical treatments.

Buddhism: Use of Human Embryos

Genome Editing Should we have the option to change DNA in babies?

KEY CONCEPT Genetics provides a basis for new medical treatments.

Presentation transcript:

To CRISPR or not to CRISPR? Group 2 Ethics of technology and science: Seminar II

CRISPR/Cas is an adaptive immune system in prokaryotes A CRISPR/Cas system has been developed as a genetic tool for precise gene modifications: –Deletions and insertions Widely used as tool in research in both eukaryotes and prokaryotes Easy design, easy execution and can be used on many different sequences Background

Setting the scene: –More knowledge about gene and gene function than a few years ago –Delivery vehicle for editing in developed cells is available –In vitro fertilization techniques already in place Unknown “off-target” effects and unknown long-term “on- target” effects Use the system to change the inherited human genetic material? Y. Wu, D. Liang, Y. Wang, M. Bai, W.i Tang, S. Bao, Z. Yan, D. Li, J. Li Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9 Cell Stem Cell 2013, 13(6):

“Should we develop the CRISPR method on humans to cure disease, knowing that it could be used for other things?” The problem

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy Proceed with caution Stop Solution 1 – ”Go Ahead”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy +: Prestige & increase funding -: Risk of bad PR & costly legal issues Proceed with caution Stop Solution 1 – ”Go Ahead”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy +: Prestige & increase funding -: Risk of bad PR & costly legal issues +: Possible huge revenue +/-: Good/Bad PR -: Costly legal issues, patent cost Proceed with caution Stop Solution 1 – ”Go Ahead”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy +: Prestige & increase funding -: Risk of bad PR & costly legal issues +: Possible huge revenue +/-: Good/Bad PR -: Costly legal issues, patent cost +: Eradicate genetic diseases +/-: “Designer babies”, unpredictable effects on society, long term effects unknown -: Identity issues, loss of diversity Proceed with caution Stop Solution 1 – ”Go Ahead”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy +: Prestige & increase funding -: Risk of bad PR & costly legal issues +: Possible huge revenue +/-: Good/Bad PR -: Costly legal issues, patent cost +: Eradicate genetic diseases +/-: “Designer babies”, unpredictable effects on society, long term effects unknown -: Identity issues, loss of diversity -: Angry Proceed with caution Stop Solution 1 – ”Go Ahead”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ Stop Solution 2 – ”Proceed with caution”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ +: Less risk of legal issues -: Less prestige, perhaps less funding (less risk & less benefit) Stop Solution 2 – ”Proceed with caution”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ +: Less risk of legal issues -: Less prestige, perhaps less funding (less risk & less benefit) +: Profit, better / more reliable product -: Delays, less profit than solution 1, more regulations Stop Solution 2 – ”Proceed with caution”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ +: Less risk of legal issues -: Less prestige, perhaps less funding (less risk & less benefit) +: Profit, better / more reliable product -: Delays, less profit than solution 1, more regulations +: More effective treatment, more informed public, legislation might prevent “designer babies” -: Delayed application of method Stop Solution 2 – ”Proceed with caution”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ +: Less risk of legal issues -: Less prestige, perhaps less funding (less risk & less benefit) +: Profit, better / more reliable product -: Delays, less profit than solution 1, more regulations +: More effective treatment, more informed public, legislation might prevent “designer babies” -: Delayed application of method -: Still angry Stop Solution 2 – ”Proceed with caution”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field Solution 3 – ”I just can’t go on...”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field +: No legal issues -: Missed opportunity, loss of funding / PR / prestige Solution 3 – ”I just can’t go on...”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field +: No legal issues -: Missed opportunity, loss of funding / PR / prestige +: No legal risk -: No revenue from CRISPR Solution 3 – ”I just can’t go on...”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field +: No legal issues -: Missed opportunity, loss of funding / PR / prestige +: No legal risk -: No revenue from CRISPR +: Slower progress but eventual eradication of genetic diseases -: Public will lose researcher’s voice of reason Solution 3 – ”I just can’t go on...”

Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead Proceed with caution Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field +: No legal issues -: Missed opportunity, loss of funding / PR / prestige +: No legal risk -: No revenue from CRISPR +: Slower progress but eventual eradication of genetic diseases -: Public will lose researcher’s voice of reason -: Angry, but about something else Solution 3 – ”I just can’t go on...”

So …. What? Solutions & Consequences Interested Parties ResearcherUniversityCompany (associated with researcher) Users/PublicReligious Organ. Solutions Go ahead +: Glory, career opportunity, scientific esteem - : Increase competition & targeted by opponents, big responsibility, risk of failure & possible negative legacy +: Prestige & increase funding -: Risk of bad PR & costly legal issues +: Possible huge revenue +/-: Good/Bad PR -: Costly legal issues, patent cost +: Eradicate genetic diseases +/-: “Designer babies”, unpredictable effects on society, long term effects unknown -: Identity issues, loss of diversity -: Angry Proceed with caution +: Possible recognition & esteem, discovery of important side effect/issues, “clean conscience” -: Might get scooped, time consuming legal ‘stuff’ +: Less risk of legal issues -: Less prestige, perhaps less funding (less risk & less benefit) +: Profit, better / more reliable product -: Delays, less profit than solution 1, more regulations +: More effective treatment, more informed public, legislation might prevent “designer babies” -: Delayed application of method -: Still angry Stop +: “Very clean conscience”, no risk of adverse effects -: No glory, less career opportunities, lose influence over development of field +: No legal issues -: Missed opportunity, loss of funding / PR / prestige +: No legal risk -: No revenue from CRISPR +: Slower progress but eventual eradication of genetic diseases -: Public will lose researcher’s voice of reason -: Angry, but about something else